Karsten Munk Knudsen, CFO of Novo Nordisk, discusses the prospect of tariffs on pharmaceuticals and the importance of the U.S. market to the Danish drugmaker.
Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG
Get this delivered to your inbox, and more info about our products and services.
Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate…
Novo Nordisk is losing market share despite its having a "comprehensive portfolio" compared to peers, the firm said.
Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026…
The Wegovy obesity drug maker on Wednesday announced plans to trim 11.5% of its workforce.
TD Cowen still sees shares of Novo Nordisk adding 6% from here.
Charlotte Reed speaks with Mike Doustdar, CEO of Novo Nordisk, after the Danish comapny hiked its 2026 full-year guidance on the…
